Western pharmaceutical giants are striking multibillion-dollar deals with Chinese biotech firms that use artificial intelligence, signaling growing confidence in China’s ability to deliver faster and cheaper innovative drugs. In June, British drugmaker AstraZeneca agreed to pay more than $5 billion to CSPC Pharmaceutical Group for access to its AI platform and a portfolio of preclinical cancer drugs — one of the largest AI biotech deals to date. CSPC, listed in Hong Kong since 1994, previously m...